Knockdown or inhibition of LIMK1 inhibits the proliferation of lung cancer, gastric cancer, colorectal cancer (CRC), and acute myeloid leukaemia (AML) cells, as well as the invasion motility of glioblastoma11,12,.18–20. Here, LIMK1 is linked to acute myeloid leukemia.